Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Acquisitions (2021 - 2022)

10x Genomics (TXG) has disclosed Acquisitions for 2 consecutive years, with $2.5 million as the latest value for Q4 2022.

  • Quarterly Acquisitions changed N/A to $2.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $4.0 million for FY2022, 26.62% down from the prior year.
  • Acquisitions hit $2.5 million in Q4 2022 for 10x Genomics, up from $1.5 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $5.5 million in Q1 2021 to a low of $1.5 million in Q3 2022.